INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Pomerantz LLP is investigating Certara, Inc. (NASDAQ: CERT) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows a significant 19% drop in Certara's stock price after the company reported a 4% decline in services revenue and a 14% decline in services bookings for the first quarter of 2026, alongside an announced exit from its regulatory business. The firm encourages affected investors to contact them regarding potential class action involvement.
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Kirby McInerney LLP is investigating Certara, Inc. (NASDAQ:CERT) due to potential federal securities law violations following a significant decline in its stock price. The investigation stems from Certara's reported first-quarter 2026 financial results, which revealed a 4% year-over-year decline in services revenue and a 14% decline in services bookings, alongside the company's decision to exit its regulatory business within the services segment. Investors who purchased Certara securities are encouraged to contact the firm to discuss their rights.
Certara’s SWOT analysis: life sciences stock faces leadership shift
Certara (NASDAQ:CERT) recently underwent a significant leadership change with Jon Resnick taking over as CEO, posing questions about the company's strategic direction amidst its growth trajectory in the biosimulation market. Despite current undervaluation and muted organic growth, Certara shows potential for accelerated revenue through new leadership's commercial focus and improving biopharma financing. The company's SWOT analysis highlights its established market position and strong EPS growth against challenges like leadership uncertainty and reliance on pharmaceutical R&D spending.
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact
Kirby McInerney LLP is investigating Certara, Inc. (NASDAQ: CERT) for potential securities laws violations after the company reported a decline in services revenue and bookings in Q1 2026. This news led to a significant 19% drop in Certara's stock price. The law firm is encouraging affected investors to contact them regarding their rights or interests.
Certara schedules RBC, William Blair and Jefferies investor appearances
Certara (Nasdaq: CERT) announced its participation in several upcoming investor conferences in May and June 2026. Management will present at the RBC CM Global Healthcare Conference, William Blair’s 46th Annual Growth Stock Conference, and the Jefferies Global Healthcare Conference. Live webcasts and 90-day replays for the RBC and Jefferies events will be available on Certara’s investor relations website.
Certara (CERT) shares slide after weak full-year guidance overshadows revenue beat
Certara's shares experienced a decline following the release of its Q1 earnings, despite beating revenue expectations. The stock slipped due to a weaker-than-anticipated full-year guidance, overshadowing the positive quarterly performance.
Certara (CERT) shares slide after weak full-year guidance overshadows revenue beat
The article reports that Certara's (CERT) shares declined after the company provided a weaker-than-expected full-year guidance, despite beating revenue estimates. This suggests investor concern over future growth prospects overriding current financial performance.
Certara (CERT) CFO Reynders gains shares as RSUs vest and new 33,222-unit grant awarded
Certara, Inc. CFO John V.W. Reynders reported equity compensation activity, with 15,757 Restricted Stock Units (RSUs) vesting and converting into common stock on May 14, 2026. This increased his direct common stock holdings to 26,466 shares. Additionally, Reynders received a new grant of 33,222 RSUs on the same date, which will vest on the earlier of one year from the grant date or the company's next annual meeting.
Certara (CERT) director adds 15,757 shares and receives 33,222 RSUs
Certara director Matthew M. Walsh engaged in equity compensation activity, with 15,757 Restricted Stock Units (RSUs) vesting and converting into common stock on May 14, 2026, increasing his direct holdings to 213,316 shares. On the same day, Walsh received a new grant of 33,222 RSUs. These new RSUs are set to vest on the earlier of one year from the grant date or the date of Certara's next annual meeting.
Certara (CERT) chairman adds 15,757 shares and 33,222 RSUs in equity awards
Certara, Inc. board chairman Eran Broshy reported equity compensation activity, not open-market trades. He received 15,757 shares as previously granted RSUs vested and gained a new grant of 33,222 RSUs. These transactions, under the company's 2020 Incentive Plan, increased his direct holdings of common stock to 50,708 shares, with additional RSUs outstanding.
Certara (CERT) director reports 5,547 shares from RSUs and 33,222 new RSUs
Certara, Inc. director Arjun Bedi reported equity compensation activity, with 5,547 previously granted RSUs vesting and converting into common stock on May 14, 2026. On the same date, Bedi received a new grant of 33,222 RSUs under the company's 2020 Incentive Plan, entitling him to one share of common stock per RSU, vesting on the earlier of one year or the next annual meeting. After these transactions, Bedi directly holds 5,547 shares of common stock.
Certara (CERT) director Crane receives 15,757 shares from RSU vesting
Certara, Inc. director Rosemary A. Crane received 15,757 shares of common stock through the vesting of restricted stock units (RSUs) on May 14, 2026. These RSUs were granted under the company's 2020 Incentive Plan, entitling her to one share of common stock per RSU at an exercise price of $0.00. Following this transaction, Ms. Crane directly owns 45,672 shares of Certara common stock, with no open-market purchases or sales reported.
Certara (CERT) reveals 2026 annual meeting director and proposal votes
Certara, Inc. (CERT) has released the final voting results from its annual meeting of stockholders held on May 14, 2026. The report details strong support for all three director nominees, Arjun Bedi, Stephen McLean, and Jon Resnick, as well as for proposals related to the ratification of RSM US LLP as the independent accounting firm and the non-binding advisory approval of executive compensation. The results were filed in an 8-K report, highlighting the key figures for votes cast for and against each item.
Certara (CERT) director converts 15,757 RSUs into common stock
Certara, Inc. director Cynthia Collins acquired 15,757 shares of common stock through the vesting of restricted stock units (RSUs) on May 14, 2026. These RSUs were granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan. Following this transaction, Collins directly holds 51,846 shares of Certara common stock.
CERTARA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Certara, Inc. following a significant drop in its stock price. The investigation stems from Certara's Q1 2026 financial results, which showed a decline in services revenue and bookings, and an announced exit from its regulatory business. The law firm is encouraging Certara stockholders who suffered losses to contact them to discuss their legal options.
CERTARA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is
Bragar Eagel & Squire, P.C. is investigating potential claims against Certara, Inc. (NASDAQ:CERT) on behalf of its stockholders. This investigation follows a significant drop in Certara's stock price after the company reported a decline in services revenue and bookings for the first quarter of 2026, along with an announcement of exiting the regulatory business within its services segment. Investors who suffered losses are encouraged to contact the firm to discuss their legal options.
Certara says AI investments will drive long-term growth – but traders are focused on one warning
Certara (NASDAQ: CERT) recently discussed its Q1 2024 earnings, highlighting strong strategic progress and a significant investment in artificial intelligence despite missing revenue estimates. The company anticipates AI will be a major driver of future growth through internal efficiencies and new service offerings, but a downward revision in full-year guidance for 2024 concerned traders, leading to a stock decline.
Certara (CERT) shares slide after weak full-year guidance overshadows revenue beat
Certara's shares have fallen after the company issued weak full-year guidance despite reporting a revenue beat. This indicates investor concern over future performance, even with a strong previous quarter.
CERTARA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has launched an investigation into Certara, Inc. following a significant drop in its stock price after the company announced its first-quarter 2026 financial results. Certara reported a year-over-year decline in services revenue and bookings, citing "softer performance from Tier 1 customers in MIDD services" and an exit from its regulatory business. Stockholders who incurred losses are encouraged to contact the law firm to discuss their legal options.
Earnings call transcript: Certara Q1 2026 results miss EPS forecast, stock drops
Certara Inc. reported mixed financial results for Q1 2026, with an EPS of $0.09, missing the forecast of $0.11, despite revenue slightly exceeding expectations at $106.9 million. The company's stock consequently dropped 19.33% post-announcement. CEO Jon Resnick outlined strategic initiatives, including a divestiture of its medical writing business, a company reorganization into MID3 and ACE segments, and increased investment in AI-integrated platforms and partnerships, such as with NVIDIA and Altasciences, to drive long-term growth and address profitability concerns.
CERTARA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP has announced an investigation into potential securities fraud against Certara, Inc. (NASDAQ:CERT). This follows Certara's first quarter 2026 financial results, which showed declines in services revenue and bookings, leading to a 19% drop in share price. The law firm is encouraging investors who purchased Certara securities to contact them regarding this ongoing investigation.
Certara (CERT) grants PSUs and RSUs to executive Robert Aspbury
Certara, Inc. (CERT) executive Robert Aspbury, President of Predictive Tech, received new equity awards on May 11, 2026, comprising 129,629 Performance Stock Units (PSUs) and two Restricted Stock Unit (RSU) awards for 246,913 and 86,419 shares. These awards, detailed in a Form 4 filing, are tied to the company's performance against total shareholder return thresholds and will vest in installments over the coming years, with some earlier PSU awards being amended and canceled.
Certara (CERT) SVP and General Counsel awarded new PSU and RSU grants
Certara, Inc. (CERT) has granted new equity awards to its SVP and General Counsel, Daniel Corcoran. On May 11, 2026, Corcoran received grants of 111,111 performance stock units (PSUs) and 74,074 restricted stock units (RSUs) under the company’s 2020 Incentive Plan. The PSUs are performance-based, with vesting dependent on Certara's total shareholder return, while the RSUs will vest in three equal installments through April 2029.
Certara (CERT) CHRO granted performance and restricted stock units in new awards
Certara, Inc. (CERT) has granted its Chief Human Resources Officer, Rona Anhalt, new performance stock units (PSUs) and restricted stock units (RSUs) on May 11, 2026. These awards, totaling 92,592 PSUs and 61,728 RSUs, are part of the company's 2020 Incentive Plan and are tied to future company performance and service conditions. The PSUs have a payout range of 0% to 200% based on total shareholder return through March 2028 and March 2029, while RSUs will vest in equal installments on April 1, 2027, 2028, and 2029.
Certara, Inc. Stock 12‑Month Price Target Cut to $7.62, Implies 50% Upside
Analysts have lowered Certara, Inc.'s average 12-month price target from $7.73 to $7.62, with individual forecasts ranging from $6 to $10 per share. Despite the cut, this updated target suggests a potential upside of approximately 50% based on the May 12 closing price. The consensus rating for Certara remains a "Buy" from 13 covering analysts.
Certara (CERT) Losses Deepen In Q1 2026 Testing Bullish Profitability Narratives
Certara (CERT) reported Q1 2026 revenue of US$106.9 million and a widened loss of US$8.8 million, or EPS of US$0.06. On a trailing twelve-month basis, losses increased to US$15.1 million with EPS of US$0.09, despite past periods of positive net income. This performance challenges bullish narratives that forecast a 57.72% annual earnings growth and a return to profitability within three years, especially with revenue growth at a modest 0.8%.
Certara, Inc. Shareholders Are Encouraged to Reach Out to
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT) following a sharp decline in stock price. This decline occurred after Certara reported a 4% year-over-year decrease in services revenue and a 14% decrease in services bookings for Q1 2026, citing "softer performance from Tier 1 customers" and "inconsistency" in its services business. The law firm is seeking to determine if Certara complied with federal securities laws and encourages affected investors to join their investigation.
Certara (CERT) Shares Slide After Weak Full-Year Guidance Overshadows Revenue Beat
Certara (NASDAQ:CERT) shares fell over 12% following disappointing full-year guidance that overshadowed slightly better-than-expected first-quarter revenue. The company reported adjusted EPS of $0.09, missing analyst estimates, and projected full-year adjusted EPS and revenue significantly below Street consensus. This revised outlook comes as Certara sold its Regulatory and Medical Writing business and is undergoing strategic reorganization.
Certara says AI investments will drive long-term growth – but traders are focused on one warning
This article from MSN discusses Certara's strategy to leverage AI investments for long-term growth. However, it notes that traders are primarily concerned with a specific warning issued by the company. Without further content from MSN, details on the AI investments or the critical warning are unavailable.
Certara, Inc. (NASDAQ:CERT) Q1 2026 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT) held its Q1 2026 earnings call, reporting an EPS of $0.09 against expectations of $0.11. CEO Jon Resnick outlined strategic initiatives to drive long-term growth, including divesting the medical writing business, reorganizing into two distinct growth areas (MID3 and ACE), enhancing AI integration with a Chief AI Officer, and forming key partnerships with NVIDIA and Altasciences. The company updated its full-year 2026 revenue guidance to reflect the divestiture, expecting $395 million to $405 million, and anticipates improved performance in the second half of the year.
Number of shareholders of Certara, Inc. – BMV:CERT
This article provides financial information for Certara, Inc. (BMV:CERT), specifically focusing on the number of shareholders. It indicates the market is closed with no trades and gives a general overview of available financial data and community features on the TradingView platform.
Certara says AI investments will drive long-term growth – but traders are focused on one warning
This article analyzes Certara's (CERT) Q4 and full-year 2023 earnings, highlighting the company's investments in AI as a key driver for future growth. Despite strong performance and future-oriented strategies, the market is focusing on a specific warning, likely concerning fiscal year 2024 guidance.
Earnings call transcript: Certara Q1 2026 misses EPS, stock drops over 17%
Certara Inc. reported mixed results for Q1 2026, missing EPS expectations ($0.09 vs. $0.11 forecast) but slightly beating revenue forecasts ($106.9 million vs. $106.1 million). The stock plunged over 17% in pre-market trading due to profitability concerns despite strong software growth. The company is undergoing strategic reorganization, integrating AI, and divesting its medical writing business to focus on core areas and improve long-term growth and consistency.
Certara, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:CERT) 2026-05-11
Certara, Inc. (NASDAQ:CERT) released its Q1 2026 earnings, with an EPS of $0.09, missing estimates by $0.02. The company's revenue reached $106.92M, which beat expectations by $815K and represented a 0.86% year-over-year increase. This article provides the earnings call presentation slides published by Certara, Inc. in conjunction with their Q1 earnings call.
Certara (CERT) Reports Strong Q1 Revenue with Strategic Growth Initiatives
Certara (CERT) announced Q1 revenue of $106.9 million, exceeding analyst expectations. The company is implementing strategic initiatives to enhance operational effectiveness and drive sustainable growth, including divesting its Medical Writing segment, focusing on two primary growth areas, and accelerating its AI program. Though Certara has a moderate GF Score™ of 68, indicating long-term potential, investors are advised to approach with caution due to challenges in profitability and the recent divestiture.
Why Did CERT Stock Fall Today?
Certara's stock (CERT) dropped over 4% in premarket trading after the company reported a Q1 profit miss and lowered its full-year 2026 earnings guidance. Despite revenue meeting Wall Street expectations, adjusted earnings per share fell short of forecasts, and the company acknowledged ongoing operational and go-to-market challenges. Certara aims to resolve these issues in the second half of the year and expects long-term growth driven by AI investments and a recent business divestiture.
Certara, Inc. (CERT) Q1 Earnings Miss Estimates
Certara, Inc. (CERT) reported Q1 earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11, and revenues of $106.92 million, which surpassed estimates. The company's stock has underperformed the S&P 500 this year, with shares down 28.4%. Despite mixed estimate revisions, Certara currently holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market.
Certara Divests Medical Writing Unit to Refocus Strategy
Certara (CERT) announced its Q1 2026 results, showing a slight revenue increase but a net loss and updated its 2026 guidance after divesting its medical writing and regulatory services unit to Veristat for up to $135 million. This strategic move aims to refocus Certara on higher-growth core operations, balancing its software and services mix, and strengthening its AI efforts. Analysts currently rate CERT stock as a Hold with an $8.00 price target.
Certara (Nasdaq: CERT) posts Q1 2026 loss, sells medical writing business
Certara (Nasdaq: CERT) reported a Q1 2026 net loss of $8.8 million, a significant drop from a net income of $4.7 million in Q1 2025, despite a slight revenue increase to $106.9 million. The company completed the sale of its global medical and regulatory writing business to Veristat for an initial $85 million cash, with potential for up to $50 million more in escrow and earn-outs. Following the divestiture, Certara updated its full-year 2026 guidance, projecting revenue of $395-$405 million and an adjusted EBITDA margin of 30-32%.
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development
Altasciences and Certara have formed a strategic partnership to enhance early-phase drug development by integrating Certara's model-informed drug development (MIDD) capabilities into Altasciences' platform. This collaboration aims to mitigate risks like toxicity and poor pharmacokinetics, leading to more efficient study designs and informed go/no-go decisions. By combining their expertise, they seek to accelerate the path to proof of concept for biotech innovators and pharmaceutical companies, aligning with FDA's push for adaptive, data-driven approaches.
Altasciences, Certara Partner to Accelerate Early-Phase Drug Development
Altasciences and Certara have formed a strategic partnership to accelerate early-phase drug development programs. The collaboration will integrate Certara's drug development services and biosimulation technology into Altasciences' Acceleration Platform, aiming to help sponsors establish earlier proof of mechanism, design more efficient studies, and make more informed decisions. This partnership seeks to address the high failure rate of preclinical drug candidates and align with new FDA guidance supporting adaptive, data-driven approaches.
Certara Insider Ups Holding During Year
Insiders at Certara, Inc. (NASDAQ:CERT) were net buyers of the company's stock over the past year, indicating optimism, particularly with one insider, William Feehery, purchasing shares at a price higher than the current market value. While there haven't been recent transactions, the earlier buying activity and current insider ownership of 2.5% suggest a reasonable alignment of interests between insiders and shareholders. The article encourages investors to review analyst forecasts for Certara and explore other undervalued companies.
Certara Insider Ups Holding During Year
Insiders at Certara, Inc. were net buyers of the company's stock over the past year, with the largest purchase being by William Feehery for US$200k at US$8.30 per share. This indicates optimism among insiders, especially as the purchase price was higher than the current share price of US$6.26. Insider ownership stands at 2.5%, suggesting a reasonable alignment of interests.
(CERT) Risk Channels and Responsive Allocation
This article provides an in-depth analysis of Certara Inc. (NASDAQ: CERT), highlighting a positive near-term sentiment that may shift and indicating that resistance is being tested. It presents three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles and holding periods, along with multi-timeframe signal analysis. The report also notes an exceptional 71.5:1 risk-reward short setup.
Certara (CERT) Sells Regulatory and Medical Writing Business for Up to $135M
Certara, Inc. (NASDAQ:CERT) has agreed to sell its regulatory and medical writing business to Veristat for up to $135 million, with the deal expected to close in Q2 2026. This divested unit generated $50 million in revenue and $17 million in adjusted EBITDA in 2025. The company plans to update its 2026 guidance after the transaction, following recent price target reductions from analysts at KeyBanc and UBS.
Certara | D: Filing D
This article is a Filing D document for Certara. It indicates a regulatory filing related to the company's activities.
Certara, Inc. (NASDAQ:CERT) Receives Average Recommendation of "Hold" from Analysts
Certara, Inc. (NASDAQ:CERT) has received an average "Hold" recommendation from thirteen analysts, with an average 12-month target price of $10.44. The company recently reported Q4 EPS of $0.09, missing the consensus of $0.11, though revenue was largely in line. Institutional investors hold a significant 73.96% of the company's stock, and Certara's shares opened at $6.24, trading within a 12-month range of $5.19 to $14.39.
Certara (Nasdaq:CERT) - Stock Analysis
This Simply Wall St *Stock Analysis* report provides a detailed overview of Certara (Nasdaq:CERT), a company offering technology-driven services and software for biosimulation in drug discovery and development. The report assesses Certara's valuation, future growth prospects, past performance, financial health, dividends, management, and ownership, highlighting that the stock is currently trading significantly below its estimated fair value. It also includes recent news, analyst commentary, and stock performance data, reflecting a more cautious sentiment from analysts recently due to revised revenue growth assumptions and perceived execution challenges.
Certara (CERT) price target decreased by 23.74% to 9.63
Certara Inc. (NASDAQ: CERT) has experienced a significant price target reduction by analysts, decreasing by 23.74% to $9.63. This adjustment reflects a notable shift in market expectations for the pharmaceutical consulting and software company.
CERT Price Today: Certara, Inc. Stock Price, Quote & Chart | MEXC
This article provides current stock price information for Certara, Inc. (CERT) on MEXC, including its market cap, trading activity, and historical performance. It also details steps on how to buy CERT on MEXC and offers a comprehensive FAQ section about Certara, Inc.'s business, financial performance, and market classification. The company specializes in biosimulation software and technology to accelerate drug discovery and development.
